دورية أكاديمية
CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up.
| العنوان: | CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up. |
|---|---|
| المؤلفون: | Elmarasi M; Department of Medical Education, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar., Elkonaissi I; Department of Hematology, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates., Elsabagh AA; Department of Medical Education, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar., Elsayed E; College of Medicine, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar., Elsayed A; Department of Medical Education, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar., Elsayed B; Department of Medical Education, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar., Elmakaty I; Department of Medical Education, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar. Electronic address: ie1703006@qu.edu.qa., Yassin M; College of Medicine, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar; Hematology Section, Medical Oncology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), P.O. Box 3050, Doha, Qatar. Electronic address: yassin@hamad.qa. |
| المصدر: | International immunopharmacology [Int Immunopharmacol] 2024 Jun 30; Vol. 135, pp. 112312. Date of Electronic Publication: 2024 May 23. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam ; New York : Elsevier Science, c2001- |
| مواضيع طبية MeSH: | Immunotherapy, Adoptive*/adverse effects , Immunotherapy, Adoptive*/methods , Neoplasms*/therapy , Neoplasms*/immunology , Receptors, Chimeric Antigen*/immunology, Humans ; Animals ; T-Lymphocytes/immunology ; T-Lymphocytes/transplantation ; Follow-Up Studies |
| مستخلص: | Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a groundbreaking and highly promising approach for the management of cancer. This paper reviews the efficacy of CAR-T therapy in the treatment of various hematological malignancies, also, with a mention of its effect on solid tumors, for which they have not received FDA approval yet. Different common and uncommon side effects are also discussed in this paper, with attention to the effect of each drug separately. By reviewing the recommendations of the FDA for CAR-T therapy research, we have extensively discussed dose-limiting toxicities. This further highlights the need for precise dosing strategies, striking a balance between therapeutic benefits and potential risks. Additionally, we reviewed the long-term follow-up of patients receiving CAR-T therapy to gain valuable insights into response durability and late-onset effects. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: CAR-T cell therapy; Cytokine release syndrome (CRS); Dose-limiting toxicities; ICANS; Progression-free survival (PFS) |
| المشرفين على المادة: | 0 (Receptors, Chimeric Antigen) |
| تواريخ الأحداث: | Date Created: 20240524 Date Completed: 20240606 Latest Revision: 20240607 |
| رمز التحديث: | 20240607 |
| DOI: | 10.1016/j.intimp.2024.112312 |
| PMID: | 38788449 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1878-1705 |
|---|---|
| DOI: | 10.1016/j.intimp.2024.112312 |